miRNAs represent an elegant mechanism of post-transcriptional control of gene expression that serves to fine-tune biological processes. These tiny non-coding RNAs (20-22 nt) bind to the 3′ untranslated region of mRNAs, thereby repressing gene expression. Recent advances in the understanding of lipid metabolism have revealed that miRNAs, particularly miR-122 and miR-33, play major roles in regulating cholesterol and fatty acid homeostasis. miR-122, the most abundant microRNA in the liver, appears to maintain the hepatic cell phenotype and its inhibition decreases total serum cholesterol. miR-33, an intronic microRNA located with the SREBP-2 gene, regulates cholesterol efflux, fatty acid β-oxidation and HDL metabolism. These findings have highlighted the complexity of lipid homeostasis, and the important role that miRNAs play in these processes, potentially opening new avenues for the treatment of dyslipidemias.
MicroRNAs
In addition to classical transcription regulators, a class of non-coding RNAs termed microRNAs (miRNAs) has emerged as critical regulators of gene expression acting predominantly at the post-transcriptional level. MicroRNAs are small (~22 nucleotide [nt] ) RNA molecules, single stranded in the mature form, that regulate gene expression in metazoan animals, plants and protozoa (2, 4) . Since their discovery in C. elegans (53, 77, 94) hundreds of miRNAs have been identified in animals, plants and viruses (6) . The miRNAs identified to date are currently curated and annotated at miRBase, hosted by the Sanger Institute as a publicly available repository (http://microrna.sanger.ac.uk/). Bioinformatic predictions and experimental approaches indicate that a single miRNA may simultaneously target more than a hundred mRNAs (27) . miRNAs thus constitute a new layer of regulatory control over gene expression programs in many organisms. In fact, human miRNAs are predicted to control the activity of more than 30-60% of all proteincoding genes (24, 27, 36) . miRNAs have been shown to be involved in a broad range of developmental and physiological processes, (2, 4, 10, 13, 22, 51, 59, 88) ; thus, their deregulation is closely linked to human diseases including cancer and heart disease and vascular disorders (1, 11, 13, 28, 90) .
In the last decades, much effort and progress has been made in understanding the molecular mechanisms that regulate cholesterol metabolism and participate in the progression of cardiovascular diseases. miRNAs are emerging as important contributors to the molecular mechanisms underlying physiological homeostasis and disease. Further understanding how miRNAs are integrated into complex genetic networks that regulate lipid homeostasis and dysregulation may potentially reveal novel therapeutic targets in this area.
MicroRNA biogenesis and function
miRNAs are encoded in diverse regions of the genome including both protein-coding and non-coding transcription units. Approximately half of miRNAs are derived from non coding RNA transcripts, while the majority of the rest are located within introns of protein-coding genes, with a very small portion (~10%) encoded by exons of long non protein-coding transcripts (mRNA-like noncoding RNAs) (20, 79, 81) . The production of the functional, 22 nt mature miRNA involves multiple processing steps ( Figure 1 ). The majority of animal miRNAs are transcribed by RNA polymerase II, as long (thousands of nucleotides) primary transcripts generating a stem-loop containing the primary miRNA (pri-miRNA) (2, 49) . In addition, RNA polymerase III has been demonstrated to generate the transcript of a subset of miRNAs (7) . The resultant pri-miRNA is then processed within the nucleus by the Microprocessor complex, which consists of a ribonuclease III (RNase III), called Drosha (54) and a RNA-binding protein DGCR8/Pasha (38) . The Microprocessor complex require a variety of accessory cofactors including DEAD box RNA helicases p68 and p72, as well heterogeneous nuclear ribonucleoproteins (hnRNPs) (35) , that may function to promote the fidelity, specificity, and/or activity of Drosha cleavage. The product of the Drosha cleavage event is a 70-100 nt hairpin-shaped precursor (pre-miRNA) that is transported to the cytoplasm via an Exportin-5 and Ran-GTP dependent mechanism (58) . In most of mammalian miRNAs, including the majority of those encoded within introns, Drosha processing occurs co-transcriptionally, before splicing of host RNA (canonical pathway). However, there is a small subset of intronic miRNAs called "miRtrons" that circumvent the Drosha pathway (50, 65, 80) . The lariat-debranching enzyme resolves the branch point to generate a pre-miRNA like hairpin that can be exported from the nucleus and further processed in the cytoplasm. The pre-miRNA is further processed to produce the ~22 nt long miRNA duplex (miRNA:miRNA*) by Dicer, another RNaseIII enzyme, which removes the terminal loop, yielding a ~22 nt RNA duplex (15, 42, 55) .
Cleavage by Drosha and Dicer are not the only RNA processing events that miRNAs can go trough during maturation. Adenosine deaminases that act on RNA (ADAR) catalyze the conversion of adenine to inosine in dsRNA. Several studies have demonstrated that primiRNAs and pre-miRNAs are substrates of ADAR enzymes which prevents Dicer processing and results in the accumulation of pre-miRNA hairpins. This editing process occurs in a tissue specific manner and may underlie tissue-specific expression of some miRNAs (46, 95) . It has been very recently shown that a subset of miRNAs, typified by the miR-144/451, are processed independently of Dicer in the cytoplasm. Instead, the secondary cleavage is carried out by Ago2, an Argonaute protein that is part of the complex that aligns the miRNA and messenger RNA (14, 16, 75) . The precursor of these miRNAs possess a stem that is uncommonly short (17 nucleotides), the mature miRNA (23 nucleotides) spans not only the length of the 5′ arm of the stem but covers all of the loop sequence. These features are predicted to be insufficient for recognition by Dicer.
The fully processsed miRNA duplex obtained via Dicer or Ago2 processing is unwound into the mature single-stranded form (guide strand) and its complementary strand (passenger strand or miRNA*). One of them will be selected and will associate with other members of the Ago protein family within the effector ribonucleoprotein complex RISC (RNA-induced silencing complex) (34, 35, 61, 70) . The intrinsic features of the duplex will determine which strand is incorporated into RISC and become a mature miRNA (49, 86) . The thermodynamic asymmetry of the miRNA duplex contributes to the strand selection (47, 82) . The strand, whose 5′ end is less stably base-paired, will be more frequently selected as the guide, while the other strand (miRNA*) will be excluded from the RISC and generally though to be degraded. However, in some instances, the passenger strand may be selected and used in gene regulation (67) . In fact, recent deep-sequencing efforts indicate that a large number of miRNA* are not degraded but rather associate to Ago1 or Ago2 (17, 31, 66, 67, 83) . In this case both strands may be functional and indicate that miRNA precursors can also be bifunctional (17, 66, 67) .
As part of the RISC, the mature miRNA guides the complex to its RNA target by WatsonCrick base-pairing interactions regulating protein synthesis (5) . When there is a perfect or near-perfect complementarity to a site(s) in the 3′ UTR of an mRNA, the target can be cleaved and degraded. However, in animals, most studied miRNAs pair imperfectly with their mRNA targets in the 3′ UTR and inhibit expression of their targets mainly through translational repression or/ and mRNA decay (71) . Recent studies have shown that miRNAs can also repress mRNA targets through binding to other regions including 5′ UTRs or protein-coding exons (25, 60, 68, 78) , and in some cases may even activate translation (39, 68, 91, 92) . However, the mechanistic details of protein synthesis inhibition by miRNAs are not well understood. Potential pathways include sequestration from ribosomes (by relocation into P bodies), blockage of translational initiation, translational repression after initiation and target deadenylation coupled to transcript degradation (57, 71) (Figure 1 ). There have been several recent reviews covering these topics (5, 10, 13, 23, 24, 49, 73, 87) .
The computational identification of miRNA targets and the validation of miRNA-target interactions represent fundamental steps in understanding the contribution of miRNAs in cell functions. Several bioinformatic tools have been developed to predict miRNA targets (5)and these algorithms collectively rely on several criteria (5) . In mammals, the most important requirement of miRNA:target interaction, although not always essential, is a contiguous base pairing of the miRNA nt 2-8, representing the "seed" region (56) . In many cases, the seed region seems to determine recognition. However in certain cases additional determinants are required, such as reasonable complementarity to the miRNA 3′ half to stabilize the interaction (nt 13-16) to compensate for inconsistent binding in the seed region (3, 5, 37, 84) . In addition, certain features of the 3′ UTR sequences surrounding the target site may boost miRNA efficacy, such as AU-rich sequences and positioning at least 50 nt from the stop codon and away from the center of long UTRs (5, 37) . Given the many criteria that influence miRNA targeting, it has become clear that the validation of predicted miRNA targets is crucial step in understanding potential (85)miRNA functions. As the understanding of miRNA binding biology increases, it can be expected that existing algorithms will become progressively more accurate.
Control of cholesterol metabolism by miRNAs
The elegance of microRNAs comes from their ability to simultaneously regulate the expression of many targets, allowing for the synchronized control of multiple genes in the same biological pathway. One such pathway is cholesterol metabolism, which has been shown to be regulated in different ways by the following miRNAs: miR-122, miR-370, miR-378/378*, miR-335, miR-125a-5p and miR-33. Among these, miR-122 was the first to be described for its role in regulating total serum cholesterol and liver metabolism, and has been the most widely studied liver miRNA. More recently however, other miRNAs have been shown to control a variety of aspects of lipid metabolism, from adipocyte differentiation to HDL biogenesis and cholesterol efflux.
miR-122 and liver metabolism
miR-122 is highly expressed by the liver, and its estimated to account for approximately 70% of all liver miRNA (68) . It was first identified due to an unusual genetic rearrangement of c-myc found in a woodchuck liver tumor, which gave rise to a non-coding, hairpin structure that was later revealed to be the precursor for miR-122 (39) . miR-122 is highly conserved, from humans to frogs, suggesting an important role for this miRNA that has been under selection pressure throughout evolution (32) . Despite its high degree of conservation, and its abundance in the liver, the targets of miR-122 were first described to be those involved in the cellular response to stress and amino acid starvation, and at first did not appear to regulate normal hepatic physiology (12) . It was only using inhibition strategies to target miR-122 in vivo that the physiological relevance of miR-122 was revealed. Esau et al. employed 2′-O-methoxyethyl phosphothioate (2'MOE) anti-sense oligonucleotides (ASO) in both normal and high-fat diet fed C57BL/6 mice for a period of 5 weeks, and examined the expression of predicted targets of miR-122, showing that miR-122 inhibition upregulated a number of predicted miR-122 targets, including ALDOA, GYS1, and CCNG1 (21). More importantly, using gene expression array analysis, the study revealed that silencing of miR-122 resulted in an upregulation of over 100 genes containing 7-8 nucleotide seed matches for miR-122 in their 3'UTR, and many of which had not been previously predicted based on bioinformatic prediction algorithms. Similarly, Elmen et al. used a complimentary strategy to identify miR-122 target genes, using locked-nucleic acid (LNA)-mediated antagonism of miR-122 in normal mice (19) . Using gene expression arrays, they identified 199 genes that were upregulated by anti-miR122 that contained at least one miR-122 recognition sites. Taken together, these results imply that endogenous miR-122 is repressing a large number of genes that become derepressed when miR-122 is silenced. Functionally speaking, the consequences of silencing miR-122 in mice are a sustained reduction in total plasma cholesterol, observed in both the LDL and HDL fractions (19, 21) . Furthermore, miR-122 antagonism in mice fed a high-fat diet resulted in a significant improvement in liver steatosis, as seen by the reductions in liver triglyceride content, and an increase in the rate of fatty acid β-oxidation (21). These results were consistent with the observation that miR-122 controls the expression of FASN, ACC1 and ACC2-all genes involved in fattyacid synthesis and oxidation. The promising results from mouse studies prompted the use of LNA-antagomirs directed against miR-122 to be test in non-human primates (18, 52) . Much like what was observed in mice, silencing of miR-122 in African green monkeys (18) and chimpanzees (52) resulted in substantial reductions in total plasma cholesterol, ranging from 20-30%, with no apparent toxicity or histopathological changes in the liver.
Certainly the targeting of miR-122 shows promise for the treatment disorders of lipid metabolism, but currently antagonism of miR-122 is being actively investigated for a therapeutic strategy in patients with hepatitis C infection. In addition to the target genes described above, miR-122 binds two positions the 5′ noncoding region in the hepatitis C viral genome, and this binding is essential to viral accumulation and propagation in infected hepatocytes (44, 45, 74) . In non-human primates, silencing of miR-122 resulted in sustained reductions in HCV viremia and improvement in liver pathology, with no evidence of viral resistance (52) . The safety and efficacy of anti-miR122 demonstrated in non-human primates prompted the first use of a miRNA-based therapeutic to enter phase 2 clinical trialMiravirsen, by Santaris Pharma A/S, is an LNA-antagomir against miR-122, and is currently being tested in patients with hepatitis C infection (26) . Phase I results in healthy subjects showed that Miravirsen is well tolerated, and the double-blind placebo controlled Phase 2 trial will certainly yield exciting results for the potential for miRNA-based therapeutics for the treatment of chronic diseases.
miR370 and its multifaceted regulation of lipid metabolism
Another miRNA, miR-370, has been described for its role in regulating cholesterol metabolism. miR-370 was first studied in a model of dominant-negative cJun overexpression, which was found to up-regulate miR-370 2.2-fold, and concomitantly downregulate carnitine palmitoyl transferase (Cpt1α)-the rate limiting step in the fatty acid β-oxidation pathway (43) . miR-370 directly targets Cpt1α by binding target sequences in the 3'UTR, which results in downregulation of Cpt1α expression, and consequently reduced fatty acid β-oxidation in culture hepatic cell lines. However, in addition to directly regulating genes involved in fatty acid metabolism, miR-370 regulates the expression of miR-122, which as described above, controls the expression of lipid and fatty acid metabolism. The authors demonstrate that over-expression of miR-370 leads to an upregulation of miR-122, and a resulting upregulation of lipogenic genes like SREBP-1c and DGAT2 (43) . Although the mechanism of this reciprocal control of miRNA expression and the consequent upregulation of certain genes is still unclear, the study highlights the complexity and the multiple layers of miRNA-mediated modulation of lipid metabolism and how our current understanding is incomplete.
miR-378/378* in adipocyte lipid biogenesis
More recently, another miRNA was found to play a role in the regulation of lipid metabolism: miR-378/378*. The authors began by investigating the effect of Ago2 knockdown on adipocyte differentiation, and surprisingly found that Ago2 had very little effect on this process, suggesting miRNAs may not be strongly influencing this pathway. In contrast, during lipid droplet formation, Ago2 deletion had profound effects on the accumulation of triacylglycerol and phospholipids (29) . This prompted the screening of miRNAs that are altered during adipogenesis in vitro, and of the few miRNAs that were altered by lipid content, miR-378/378* was most highly upregulated. Interestingly, miR-378/378* is located within the peroxisome proliferator-activated receptor gamma coactivator-1 beta (PGC1β), and the two transcripts are co-transcribed during adipocyte differentiation (29, 87) . Over-expression of miR-378/378* lead to increased lipid droplet size, and accumulation of triacylglycerol in 3T3-L1 adipocytes, without demonstrable effects on fatty acid β-oxidation. Moreover, over-expression of miR-378/378* resulted in increased triacylglycerol synthesis, whereas knockdown of miR-378/378* caused a decrease in triacylglycerol synthesis. In searching for possible targets of miR-378/378*, the authors performed a gene expression array, but surprisingly found that in response to overexpression of miR-378/378*, when target genes would be expected to be downregulated, there were eight sets of genes that were upregulated in response to miR-378/378*. These included genes involved in fatty acid synthesis (i.e. FAS, SCD-1, resistin), which would help to explain the increased triacylglycerol synthesis in the presence of miR-378/378*. Interestingly, none of the over 20 predicted targets of miR-378/378* that were tested were found to be true targets of this miRNA, and surprisingly there was an increase in the transcriptional activity of C/EBPα and β. The authors speculate that this could be an indirect effect, through the miR-378/378*-mediated downregulation of a transcriptional repressor of the C/EBPs, or else could suggest that miR-378/378* is acting to enhance transcriptional activity of C/EBPα and β by an atypical mechanism. Although this hypothesis requires further study, it is clear that the miRNA-mediated regulation of adipocyte differentiation and adipogenesis is multifaceted and not as straightforward as it may first appear, representing another layer of complexity of miRNA regulation.
miR-33 regulates lipid metabolism
Recently, several groups independently reported that the SREBP-2 locus transcribes not only the mRNA for this transcriptional regulator of cholesterol uptake and synthesis, but also a highly conserved microRNA, miR-33a, that represses multiple genes involved in cellular cholesterol trafficking (63, 64, 76) . miR-33a has been highly conserved during evolution and is present in the genomes of flies to vertebrates. Notably, a second isoform of miR-33, miR-33b, is found within Srebf-1 in a more limited number of species (64) .
Although present in primates, miR-33b is absent in rodents, and to date has been less well studied than miR-33a. As has been reported for several intronic miRNAs, miR-33a and miR-33b are co-transcribed with their host genes under conditions that regulate SREBP-2 and SREBP-1, respectively. Interestingly, despite a two-nucleotide variation in the mature forms of miR-33a and miR-33b, these miRNAs similarly target a variety of lipid metabolism associated genes including Abca1, Crot, Cpt1a, Hadhb, and Ampkα, suggesting overlapping functions (Davalos et al., manuscript under revision).
Although the genomic location of miR-33a was reported in 2004, a number of years passed before the significance and the functional consequences of this location were established. Yet in a series of parallel studies published in 2010, miR-33 was identified as a key posttranscriptional regulator of cellular cholesterol homeostasis by three independent laboratories (63, 64, 76) . Using an unbiased microarray approach, our group identified miR-33a as one of twenty microRNAs altered by cholesterol content in macrophages (76) . Under cholesterol-depleted or cholesterol-enriched conditions, expression of miR-33 paralleled that of SREBP-2, suggesting that these genetic elements are co-regulated. Furthermore, we showed that dietary cholesterol alters hepatic miR-33 expression levels in vivo, in both normal and hypercholesteromic mice. Two other groups, Najafi-Shoushtari et al. and Marquardt et al., uncovered the presence of miR-33 through in silico bioinformatic analysis of SREBP loci. These investigators also showed that miR-33a is co-transcribed along with Srebf-2 in both hepatocytes and macrophages, and that the expression of miR-33a and Srebf-2 is comparable across many tissues (63, 64) .
Despite their different approaches, all three groups quickly honed in on the top predicted gene target of miR-33, the ATP-binding cassette transporter ABCA1 that is responsible for the movement of free cholesterol out of the cell. The 3'UTR of Abca1 contains three highly conserved binding sites for miR-33a and/or miR-33b and the expression of ABCA1 mRNA and protein is strongly repressed by miR-33 overexpression in a variety of cell types (63, 64, 76) . Analysis of the 3'UTR of Abca1 revealed that the targeting by miR-33 is direct and specific, as mutations in these sites results in the relief of the repression of Abca1 by miR-33 (63, 64, 76) . Functionally, over-expression of miR-33 in macrophages and hepatocytes decreased cholesterol efflux to apoA1-a key step in the generation of HDL and reverse cholesterol transport (RCT). Moreover, the inhibition of endogenous miR-33 results in an increase in expression of ABCA1 protein, and a concomitant increase in cholesterol efflux to apoA1, indicating a physiological relevant role for this miRNA in regulating ABCA1 (63, 64, 76) .
In addition to ABCA1, our study identified two other genes involved in cholesterol mobilization as targets of miR-33: ABCG1 (63, 76) , which mobilizes cellular free cholesterol to more lipidated HDL particles, and NPC1 (76) , which transports cholesterol from lysosomal compartments to other parts of the cell in need (Figure. 2) . Interestingly, miR-33 targeting of these two genes differs in mice and humans. The 3'UTR of the mouse Abcg1 gene contains two miR-33 binding sites, however these sites are not conserved in the human 3'UTR. miR-33 overexpression in macrophages confirmed that miR-33 inhibits ABCG1 expression in cells of mouse but not human origin, indicating species-specific regulation of this gene by miR-33 (63, 76) . The functional consequence of ABCG1 targeting in cells of mouse origin was demonstrated by a decrease in cholesterol efflux to HDL after over-expression of miR-33 (76) . Furthermore, the 3'UTR of human Npc1 contains two miR-33 binding sites, resulting in repression of NPC1 protein expression by miR-33 in human macrophages and hepatocytes. NPC1 acts in concert with ABCA1 to efflux cholesterol to apoA1 (93) , indicating that miR-33 represses a second part of the cellular cholesterol export pathway in humans. However, the 3'UTR of mouse Npc1, which contains only one miR-33 binding site, is not repressed (76) . Together, these results indicate that miR-33 targets multiple genes in the pathway regulating efflux of cholesterol to HDL.
miR-33 Regulates HDL levels in vivo
HDL plays a key role in the removal of excess cholesterol from the body through the reverse cholesterol transport (RCT) pathway. ABCA1 and ABCG1 have important functions in the RCT pathway: (1) In the liver, ABCA1 mediates the initial lipidation of apoA1 to form nascent HDL particles and (2) In peripheral tissues, particularly macrophages in atherosclerotic lesions, ABCA1 mediates the efflux of cellular cholesterol to this nascent HDL, while ABCG1 contributes to the further lipidation of HDL. The observations that miR-33 could reciprocally control ABCA1 and ABCG1 expression upon activation of SREBP-2 thus lead to the hypothesis that miR-33 may control HDL levels in vivo. Using a variety of approaches, from viral delivery of antisense oligonucleotides to locked nucleic acid (LNA) inhibitors, it was demonstrated that modulation of miR-33 levels in vivo alters hepatic ABCA1 protein expression and circulating HDL (63, 64, 76) . In vivo overexpression of miR-33 decreased HDL levels by a 25%, whereas its inhibition increased circulating HDL by 25-30%. Notably, these experiments were performed in both normal and high-fat diet fed mice, indicating that inhibition of miR-33 results in a functional increase in HDL even when miR-33 (and SREBP-2) levels would be predictably low. Together these data indicate that anti-miR33 treatment to elevate ABCA1 levels and increase HDL levels holds promise for the treatment and/or prevention of coronary artery disease (CAD), in which an underlying risk factor is low levels of HDL.
Shortly after the demonstration that miR-33 regulates HDL levels in vivo, this finding was confirmed in a molecular genetic-causation study by Horie et al. These investigators generated mice in which miR-33 was deleted from the intron of SREBP-2, without affecting the expression of the host gene. These mice, which were viable and fertile, showed increased hepatic ABCA1 expression and a 25-40% increase in circulating HDL levels (40) . Notably, whereas no differences in male and female mice were observed in studies using synthetic inhibitors, female miR33 -/-mice show larger increases in circulating HDL than their male counterparts. The molecular mechanisms of this difference are currently unknown. Interestingly, the increase in HDL in miR33 -/-mice appears to be in the larger, more lipidated HDL fractions, with no changes observed in the smaller HDL fractions (40) . This increase in HDL particle size may be as a result of efflux of cholesterol to HDL from extrahepatic tissues into the reverse cholesterol transport pathway, where ABCA1 and ABCG1 plays important roles.
miR-33 Targets Genes Involved in Fatty Acid Metabolism
In addition to cholesterol transport, miR-33a and miR-33b were recently reported to target genes involved in the β-oxidation of fatty acids. We and others showed that miR-33 binding sites are highly conserved in the 3'UTR of Cpt1a, Crot and Hadhb, from humans to chicken ((30) and Davalos et al., manuscript under revision). Each of these genes plays a distinct role in the fatty acid oxidation pathway: CPT1a is required for coupling of acetyl CoA to carnitine, allowing for transport of medium-and long-chain fatty acids to the mitochondria for β-oxidation (8, 62, 72) . CPT1a is the rate-limiting step for this process, and is not surprisingly one of the most highly regulated members of the β-oxidation pathway (8, 62, 72) . Similarly, CROT is a peroxisomal enzyme that is required for the coupling of shortchain fatty acids to carnitine, also transporting them into the mitochondria. Finally, HADHB is required for the last three steps in the β-oxidation pathway in the mitochondria (8, 62, 72) . Analysis of the 3'UTR activity of Cpt1a, Crot and Hadhb revealed that miR-33 targets these genes in the fatty acid oxidation pathway, and over-expression of miR-33 in hepatocytes decreases CPT1a and HADHB protein expression.
Gerin et al. proposed that when SREBP-2 is activated, miR-33a would also target genes involved in cellular β-oxidation of fatty acids, which is known to occur during states of cholesterol depletion. Indeed, they demonstrated that overexpression of miR-33a reduced cellular fatty acid β-oxidation (30) . While this group focused their studies on miR-33a, perhaps of greater interest is the role of miR-33b in this process, which is encoded within Srebp-1. SREBP1 is upregulated during states of insulin excess, when cellular fatty acid β-oxidation is reduced -possibly as a result of upregulation of miR-33b. Indeed, work from our group showed that activation of SREBP-1 with an LXR agonist leads to increased expression of miR-33b (Davalos et al., manuscript under revision). Furthermore, we found that miR-33a and miR-33b similarly target the 3′ UTR activity of Crot, Cpt1a, Hadhb, and Ampkα, indicating that both isoforms likely play a role in the regulation of these genes (Davalos et al., manuscript under revision). Taken together, these data suggest that antimiR-33 treatment may be a viable therapy for metabolic syndrome, in which both low HDL and hypertriglyceridemia are key contributors to the disease. The data to date indicate that inhibition of miR-33 would both increase HDL levels and fatty acid oxidation, however further in vivo testing of this in animal models will be challenging due to the lack of conservation of miR-33b in lower mammals such as mice.
Conclusions
It has become increasingly recognized that microRNAs play a prominent role in regulating biological processes. Although this field is still in its infancy in the area of lipid metabolism, there is little doubt that additional microRNAs will be identified in the near future that regulate lipid metabolism pathways. Many of these may have potential as targets for the treatment of metabolic disorders, but the development of such therapeutics faces numerous challenges, including target identification, specificity, mode of delivery and length of action. Perhaps most critical will be understanding the full range of targets that a specific miRNA or anti-miRNA affects. As an example, anti-miR-122 is in phase II clinical trials for the treatment of chronic HCV infection, however it remains unclear which direct targets of miR-122 account for its profound effects in the liver. Such an understanding may take years of basic research to untangle. Anti-miR-33 appears to hold promise as a therapy to raise HDL in the treatment of cardiovascular disease and metabolic syndrome. Studies of the effects of anti-miR-33 in animal models of atherosclerosis will undoubtedly be revealed shortly and will likely provide valuable information on the efficacy of such a treatment. The success of phase I clinical trials of anti-miR-122 and studies of this drug in primates are encouraging, and similar studies of anti-miR-33 are eagerly awaited. • miR-122 is the most highly expressed microRNA in the liver and appears to maintain the hepatic cell phenotype.
• Inhibition of miR-122 decreases total serum cholesterol in mice and primates.
• Anti-miR-122 is in phase II clinical trial development for the treatment of chronic HCV.
miR-33
• miR-33a and miR-33b are intronic microRNAs located within the SREBP-2 and SREBP-1 genes, respectively.
• miR-33a/b are co-regulated with their host genes.
• miR-33a/b coordinately target genes involved in cellular cholesterol export and fatty acid β-oxidation.
• inhibition or targeted deletion of miR-33 increases circulating HDL levels in mice.
Future issues
• Identification of novel microRNAs controlling lipid metabolism It is clear from the work to date that microRNAs can play a key role in regulating lipid metabolism pathways and there remains much to be discovered. In the coming years it is likely that the identification of novel microRNAs and their targets will provide insight into the complex network that regulates lipid homeostasis. One of the many challenges will be to fully characterize these emerging candidates and confirm their physiological relevance.
• Translation of basic research on microRNAs into therapeutics The development of miRNA-based therapeutics faces numerous challenges, including identification of the full spectrum of targets, and a better understanding of their specificity, persistence and length of action. The success of phase I clinical trials of anti-miR-122, along with the studies of this drug in primates, are encouraging, and suggest that it is not unlikely that anti-microRNA therapies may become viable therapeutics in the not so distant future.
• The therapeutic potential of antagonizing miR-33 Anti-miR-33 appears to hold promise as a therapy to raise HDL, however several key questions remain to be answered. For example, is the HDL generated by anti-miR-33 treatment functional (ie. Can it promote cholesterol efflux)? Also, what is the impact of anti-miR-33 on atherosclerosis? Finally, as with anti-miR-122, understanding the full complement of miR-33 targets will be necessary before this can be tested therapeutically. miRNA biogenesis pathway. miRNAs are transcribed in the nucleus by RNA polymerase from independent miRNA genes located in polycistronic transcripts or introns of proteincoding genes into primary transcripts (pri-miRNAs). Pri-miRNAs are processed in two steps in the nucleus and cytoplasm by the RNase III type endonuclease Drosha and Dicer, respectively, in complexes with dsRNA-binding domains proteins, DGCR8 and TRBP as indicated. In the canonical pathway, Drosha-DGCR8 processes the transcript to a stem-loopstructured precursor (pre-miRNA). Alternatively miRtrons, a subset of miRNAs derived from introns, may be processed into pre-miRNAs by the spliceosome and the debranching enzyme. Both canonical miRNAs and miRtrons are exported to the cytoplasm via Exportin 5, where they are further processed by Dicer-TRBP to yield ≈ 20-bp miRNA duplexes. One strand is selected to function as the mature miRNA and loaded into the RNA-induced silencing complex (RISC) containing components of the Argonaute family (Ago 1-4), while the partner miRNA* strand is preferentially degraded. A subset of miRNAs, exemplified by miR-451, are produced independently of Dicer through recognition by Ago2. The mature miRNA produced by these two mecahnisms leads to translational repression or degradation of the target mRNA. Animal miRNAs usually show only partial complementarity to the target mRNA promoting translational repression (initiation and post initiation steps) or deadenylation coupled to exonucleolytic degradation of target mRNA. mRNAs repressed by deadenylation or at the translation-initiation step can be moved to P-bodies for either degradation or storage. induce the co-transcription of miR-33b and miR-33a, respectivly. These pri-miRNAs are sequentially processed by Drosha and Dicer, and loaded into the RNA-induced silencing complex (RISC). As a result of binding target sites in the 3'UTR, miR-33a/b simultaneously inhibit the expression of genes involved in fatty acid metabolism (CROT, CPT1a and HADHB) and cholesterol transport (ABCA1, ABCG1 and NPC1). The outcome of miR-33 targeting of these genes is reduced fatty acid β-oxidation, reduced cholesterol efflux and reduced lipidation of apoA1 and HDL particles. Therapeutic targeting of miR-33 and miR-122 in atherosclerosis Upon treatment with antimiR33 inhibitors, hepatic miR-33 levels are reduced, resulting in increased expression of target genes ABCA1 and ABCG1 in the liver. This results in enhanced HDL biogenesis and an increase in circulating HDL which can promote reverse colesterol transport from tisúes, including from lesional macrophage foam cell macrophage. In addition, anti-miR-33 may directly target these lesional macrophages, upregulating ABCA1 and ABCG1 expression, further enhancing cholesterol removal from the plaque. Antagonism of miR-122, the most highly expressed miRNA in the liver, decreases circulating cholesterol, particularly LDL, via as yet unspecified mechanisms. Notably, anti-miR-122 also decreases propagation of Hepatitis C virus in the liver and is currently in clinical trial for this application.
